Alu hypomethylation and MGMT hypermethylation in serum as biomarkers of glioma

作者：Mingjie Gong, Wei Shi, Jing Qi, Guoping Shao, Zhenghua Shi, Junxiang Wang, Jian Chen, Rong-tao Chu · 发表于：Oncotarget · 年份：2017 · DOI：10.18632/oncotarget.20012 · 被引用次数：16 · 研究领域：Glioma Diagnosis and Treatment、Epigenetics and DNA Methylation、MicroRNA in disease regulation

// Mingjie Gong 1 , Wei Shi 2 , Jing Qi 3 , Guoping Shao 1 , Zhenghua Shi 1 , Junxiang Wang 1 , Jian Chen 2 and Rongtao Chu 1 1 Department of Neurosurgery, Changshu No. 2 People’s Hospital (The 5th Clinical Medical College of Yangzhou University), Changshu, Jiangsu Province, China 2 Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China 3 Comprehensive Surgical Laboratory, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China Correspondence to: Rongtao Chu, email: shiweisjwk@126.com Keywords: Alu, MGMT, serum, DNA, glioma Received: March 29, 2017     Accepted: June 12, 2017     Published: August 07, 2017 ABSTRACT In order to improve prognosis of glioma patients, better tools are required for early diagnosis and treatment. Serum cell-free DNA methylation levels of Alu, MGMT, P16, RASSF1A from 124 glioma patients and 58 healthy controls were detected by the bisulfite sequencing. The median methylation level of Alu was 46.15% (IQR, 36.57%–54.00%) and 60.85% (IQR, 57.23%–65.68%) in glioma patients and healthy controls respectively. The median methylation level of MGMT in glioma samples was 64.65% (IQR, 54.87%–74.37%) compared to 38.30% (IQR, 34.13%–45.45%) in healthy controls, and all revealed significant differences including P16. However, the median methylation level of RASSF1A was not significantly altered in glioma patients. Furthermore,...